Skip to main content
Figure 4 | Orphanet Journal of Rare Diseases

Figure 4

From: An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A

Figure 4

Response to PXT3003 on clinical scales (Full Analysis Set, n  = 80). Mean % (s.e.m.) of improvement from baseline per group at 12 months for CMTNS (a) and ONLS (b). Sample sizes: Placebo (n = 19), LD (n = 21), ID (n = 21), HD (n = 19).

Back to article page

Orphanet Journal of Rare Diseases

ISSN: 1750-1172